#USA #NASDAQ #PTC Therapeutics #stock options #Warren

PTC Therapeutics Approves Stock Options and Restricted Stock Units

Warren, NJ - On October 1, 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT) disclosed the approval of significant stock options and restricted stock units for its new employees. The announcement details the grant, which is part of PTC's efforts to enhance their employment compensation strategies under the guidelines set by Nasdaq.

On September 28, 2025, the company granted non-statutory stock options to purchase a total of 19,475 shares of common stock. Additionally, 39,060 restricted stock units (RSUs) were allocated, which provide the right to receive one share of common stock upon vesting. This initiative is a core component of the compensation package designed for 48 newly recruited employees, reflecting PTC's commitment to attracting top talent in the biopharmaceutical sector.

These inducement grants were sanctioned by PTC's Compensation Committee as a strategic initiative to meet the growing demands of the company and ensure a highly motivated workforce aligned with the company’s objectives. The fact that these grants are being executed as part of the employment process signifies PTC's binding commitment to enhancing the overall employee experience, and also its recognition of the competitive landscape in the biotech industry.

All stock options come with an exercise price set at $58.99 per share, aligning with the closing stock price on September 26, 2025. The options feature a ten-year term and follow a structured vesting schedule over a four-year period. Notably, 25% of the granted shares will vest on the one-year anniversary of the employee's hire date, with increments of 6.25% vesting every three months thereafter, provided the employee maintains continuous service with the firm.

Similarly, the RSUs will vest in equal percentages of 25% each year, commencing on the annual anniversary of the hire date and maintaining the same continuous service requirement. This plan is designed to not only incentivize new hires but also align their goals and ambitions with those of the company's long-term growth objectives.

About PTC Therapeutics, Inc.
PTC Therapeutics stands out as a global biopharmaceutical entity dedicated to discovering, developing, and commercializing clinically differentiated medications. Their focus primarily lies in serving children and adults grappling with rare disorders. The company is leading the charge with a diversified pipeline, seeking to transform the lives of patients in need of advanced medical solutions. With a strategy catering to both scientific expertise and commercial sustainability, PTC aims to deliver optimal value to its stakeholders and the wider community.

For more detailed information about PTC Therapeutics, interested parties can visit their official website at www.ptcbio.com and follow the company on social media platforms including Facebook, X (formerly Twitter), and LinkedIn.

Media Contact:

• - Investors: Ellen Cavaleri, +1 (615) 618-8228, [email protected]
• - Media: Jeanine Clemente, +1 (908) 912-9406, [email protected]